What is the role of chromatography in vaccine manufacturing?

Chromatography plays a central role in vaccine manufacturing by separating and purifying the active biological components from the complex mixture of host cell proteins, DNA, lipids, and other process-related impurities generated during upstream production. Without robust chromatographic purification, it would be impossible to achieve the purity and safety standards required for a biological medicine intended for human use. The sections below unpack the specific steps, mechanisms, and regulatory context that define how chromatography functions within a modern vaccine production workflow.

Which chromatography steps are used in vaccine downstream processing?

Downstream processing in vaccine manufacturing typically involves a sequence of chromatography steps designed to progressively increase purity. These steps are generally organized into three stages: capture, intermediate purification, and polishing. Each stage uses a different chromatographic mode, selected based on the properties of the target molecule and the impurities present at that point in the process.

The most commonly applied chromatographic techniques in vaccine downstream processing include:

Affinity chromatography: exploits specific molecular interactions to selectively bind the target antigen or viral vector
Ion exchange chromatography (IEX): separates molecules based on surface charge, effective for both binding the product and removing charged impurities
Size exclusion chromatography (SEC): separates by molecular size, typically used late in the process for final polishing
Hydrophobic interaction chromatography (HIC): exploits differences in surface hydrophobicity, useful for removing aggregates and host cell proteins
Mixed-mode chromatography: combines two or more separation mechanisms, offering flexibility when single-mode resins are insufficient

The specific combination and order of these techniques depends on the nature of the vaccine antigen, the host system used for production, and the impurity profile that must be addressed before the product meets release specifications.

How does chromatography remove impurities from vaccine intermediates?

Chromatography removes impurities from vaccine intermediates by exploiting physicochemical differences between the target molecule and the contaminants present in the feedstream. The target antigen or viral particle binds selectively to the chromatography resin under defined conditions, while impurities either flow through or are washed away before the product is eluted.

In a typical bind-and-elute mode, the feedstream is loaded onto a column under conditions that favor binding of the product. A wash step then removes loosely associated impurities such as host cell proteins and residual DNA. The product is subsequently released by changing the buffer conditions, for example by altering salt concentration, pH, or polarity.

Alternatively, in flow-through mode, the conditions are set so that impurities bind to the resin while the product of interest passes through unretained. This approach is often used in later purification stages where the product is already partially pure and the goal is to remove trace contaminants rather than capture the product itself.

The effectiveness of each step depends on careful optimization of loading conditions, wash buffers, and elution gradients. In the context of downstream processing vaccines, this optimization work is typically performed at laboratory scale before being translated to larger systems.

What is the difference between capture, intermediate, and polishing steps?

The three stages of chromatographic purification serve distinct purposes and are designed to address different challenges at different points in the purification sequence. Capture concentrates and stabilizes the product. Intermediate purification removes the bulk of process-related impurities. Polishing achieves the final purity level required for a safe biological product.

Each stage has a defined role:

Capture: The first chromatography step after clarification. The feedstream is dilute, complex, and potentially unstable. The primary goal is to rapidly concentrate the product and remove the largest volume of contaminants. Affinity chromatography is frequently used here because of its high selectivity.
Intermediate purification: The product is now concentrated but still contains significant levels of host cell proteins, residual DNA, aggregates, and process additives. Ion exchange or hydrophobic interaction chromatography is applied to reduce these impurities to acceptable levels.
Polishing: The final step targets trace impurities that remain after the intermediate stage, including product-related variants such as aggregates, fragments, or misfolded forms. Size exclusion chromatography and mixed-mode resins are commonly applied here to achieve the final purity specification.

Together, these three stages form an orthogonal purification strategy, meaning each step targets a different property of the molecules involved. Orthogonality is important because it reduces the risk of impurities that survive one step also surviving the next.

How does chromatography differ between viral vector and protein-based vaccines?

Chromatography strategies differ significantly between viral vector vaccines and protein-based vaccines because the size, structure, and physicochemical properties of the target molecules are fundamentally different. Viral vectors are large, complex particles that require gentle handling and resins with large pore sizes, while protein antigens are smaller molecules that can be purified using conventional column formats.

Viral vector vaccines

Viral vectors such as adeno-associated viruses (AAV) or adenoviruses are considerably larger than typical proteins, which limits the use of standard bead-based resins. Affinity chromatography using ligands specific to the viral capsid is often the method of choice for capture. Ion exchange chromatography is also widely applied but requires resins engineered to accommodate the size of intact viral particles. A key challenge in viral vector purification is separating full capsids (containing the genetic payload) from empty capsids, which requires techniques sensitive to small differences in particle density and charge distribution.

Protein-based vaccines

Protein antigens, including recombinant subunit vaccines and virus-like particles, are more amenable to conventional chromatographic approaches. Affinity chromatography, ion exchange, and hydrophobic interaction chromatography can all be applied using standard resin formats. The main purification challenge is removing host cell proteins and DNA while preserving the structural integrity and immunogenic properties of the antigen. Protein-based vaccine purification workflows are generally more established and benefit from a broader base of platform knowledge developed in the broader biopharmaceutical industry.

What are the regulatory requirements for chromatography in GMP vaccine production?

In GMP vaccine production, chromatography steps must be validated, controlled, and documented to demonstrate that they consistently deliver a product of defined purity, potency, and safety. Regulatory frameworks such as those issued by the EMA, FDA, and ICH require manufacturers to characterize each chromatography step, define its operating parameters, and demonstrate that it removes specific impurities to acceptable levels.

Key regulatory expectations for chromatography in vaccine manufacturing include:

Process validation studies demonstrating consistent removal of host cell proteins, residual DNA, and adventitious agents
Resin lifetime studies showing that column performance is maintained over multiple cycles
Cleaning validation confirming that carryover between product batches is below defined limits
Column qualification and requalification procedures aligned with IQ/OQ/PQ principles
Full audit trails and batch records supporting 21 CFR Part 11 or equivalent electronic data integrity requirements

It is worth noting that regulatory requirements apply to the process and the facility, not to the instrument in isolation. Manufacturers are responsible for demonstrating that their entire purification process, including the chromatography steps, meets the applicable standards. Instruments used in GMP environments must be qualified, but qualification is a site-specific activity carried out by the manufacturer’s quality team.

How is chromatography being scaled from lab to manufacturing in vaccine production?

Scaling chromatography from laboratory to manufacturing scale in vaccine production involves translating the operating parameters established at small scale to progressively larger column formats while maintaining consistent separation performance. The fundamental principle is that linear velocity, residence time, and buffer volumes per column volume should remain constant across scales, so that the resin experiences the same conditions regardless of column size.

In practice, scale-up introduces engineering challenges that are not present at laboratory scale. Larger columns require more precise flow distribution across the column bed, and any non-uniformity in packing or flow can create zones of poor separation. Buffer preparation, hold times, and system dead volumes also become more significant as column dimensions increase.

The scale-up process typically follows a stepwise path: process development at bench scale, followed by pilot-scale runs to generate process understanding data, and then transfer to manufacturing scale with defined acceptance criteria. Each transition requires careful comparison of chromatographic profiles and impurity clearance data to confirm that the process behaves predictably at the new scale.

For research teams in the Benelux working on vaccine purification development, having access to well-characterized laboratory-scale chromatography systems is essential for generating the process knowledge that supports successful scale-up decisions.

How ChemSPX supports chromatography in vaccine research

ChemSPX supports laboratories and research groups across the Benelux with high-end chromatography instrumentation for purification development and process optimization. Whether you are working on protein antigen purification, viral vector downstream processing, or method development for a new vaccine platform, ChemSPX’s team of Sales Engineers and Product Specialists can advise on the right system for your application.

Expert advice on chromatography system selection for vaccine purification workflows
Application-level support from specialists with experience in biological purification
IQ/OQ installation and qualification services aligned with GMP, GLP, and 21 CFR Part 11 requirements
Ongoing service and maintenance to keep instruments performing reliably in regulated environments
Coverage across the Benelux region from offices in the Netherlands and Belgium

If you are developing or scaling a vaccine purification process and want to discuss which chromatography instruments best fit your workflow, get in touch with ChemSPX to speak with a specialist.

Foire aux questions

How do you choose the right resin for a new vaccine purification process when there is no established platform to follow?

Start by characterizing the physicochemical properties of your target antigen — its isoelectric point, hydrophobicity, size, and any known ligand interactions — and map these against the impurity profile of your feedstream. Resin screening kits from major suppliers allow you to test multiple chemistries in parallel at small scale before committing to a full column format. If no single-mode resin delivers adequate selectivity, mixed-mode resins are worth evaluating early, as they can resolve separations that conventional IEX or HIC cannot achieve alone.

What are the most common mistakes made during chromatography method development for vaccine purification?

One of the most frequent mistakes is over-optimizing a single step in isolation without considering how changes propagate through the rest of the purification train. For example, modifying the elution buffer of a capture step may improve yield but introduce a conductivity or pH condition that compromises the binding performance of the next IEX step. Another common error is under-characterizing the feedstream before method development begins — without a clear picture of which impurities are present and at what levels, it is difficult to set meaningful acceptance criteria or detect when a step is underperforming.

How many chromatography cycles can a resin typically withstand before it needs to be replaced, and how is this determined?

Resin lifetime varies considerably depending on the resin chemistry, the nature of the feedstream, and the cleaning protocols applied between cycles, but many resins used in biopharmaceutical manufacturing are validated for 100–200 cycles or more. Lifetime is determined through resin lifetime studies in which column performance — measured by parameters such as dynamic binding capacity, impurity clearance, and peak resolution — is monitored over a defined number of cycles. Regulatory guidelines require manufacturers to establish a validated resin lifetime and to demonstrate that product quality remains within specification throughout that lifetime.

Is it possible to use a single chromatography step instead of a three-stage sequence to reduce process complexity?

In some cases, particularly for simpler protein antigens produced in well-controlled expression systems, it may be feasible to achieve the required purity with fewer than three chromatography steps, especially when a highly selective affinity step is available. However, regulatory expectations generally require manufacturers to demonstrate adequate clearance of host cell proteins, residual DNA, and adventitious agents, which is difficult to achieve with a single step across diverse feedstream compositions. For viral vectors and more complex antigens, a multi-step orthogonal strategy remains the most robust and defensible approach for GMP manufacturing.

What analytical methods are needed alongside chromatography to confirm that purification is working correctly?

Chromatography development should always be supported by a panel of in-process analytics to confirm both product quality and impurity clearance at each step. Key assays include ELISA or activity-based assays for product quantification, host cell protein (HCP) ELISA, residual DNA quantification by qPCR, SDS-PAGE or capillary electrophoresis for purity profiling, and dynamic light scattering or analytical SEC for aggregate monitoring. For viral vector vaccines, additional assays such as full-to-empty capsid ratio determination by analytical ultracentrifugation or charge-detection mass spectrometry are increasingly expected by regulators.

What should researchers consider when transferring a chromatography method developed in-house to a contract development and manufacturing organization (CDMO)?

A successful technology transfer requires comprehensive process documentation that goes beyond the chromatography parameters themselves — it should include the analytical methods used to assess each step, the acceptance criteria applied at each stage, and the process understanding data that explains why specific conditions were chosen. Differences in equipment, resin lot variability, and water quality between sites can all affect column performance, so it is advisable to include a comparability protocol with defined equivalence criteria before the transfer is considered complete. Running at least one parallel batch at both sites during the transition period helps identify discrepancies early and reduces the risk of process failures after full handover.

How does process intensification, such as continuous chromatography, apply to vaccine manufacturing, and is it suitable for all vaccine types?

Continuous chromatography formats such as periodic counter-current (PCC) or simulated moving bed (SMB) systems can significantly increase resin utilization and process throughput compared to traditional batch column chromatography, making them attractive for high-volume vaccine manufacturing scenarios. These approaches are most readily applicable to well-characterized protein antigens where the binding and elution behavior is predictable and the feedstream is relatively consistent. For viral vectors, continuous chromatography is more challenging to implement due to the sensitivity of intact particles to shear stress and the tighter process windows required, though research in this area is advancing and some platforms are beginning to demonstrate feasibility at pilot scale.

Articles connexes

Ce contenu a été généré à l'aide de l'IA et peut contenir des erreurs.

Choose your region: